Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Highland Capital Management LLC

Highland Capital Management LLC boosted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 67,700 shares of the company’s stock after buying an additional 6,050 shares during the period. Highland Capital Management LLC’s holdings in Takeda Pharmaceutical were worth $896,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at about $601,000. Verition Fund Management LLC acquired a new stake in Takeda Pharmaceutical during the third quarter valued at approximately $1,533,000. HighTower Advisors LLC boosted its holdings in Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after buying an additional 81,653 shares in the last quarter. XTX Topco Ltd acquired a new position in Takeda Pharmaceutical in the third quarter worth approximately $957,000. Finally, Creative Planning increased its holdings in shares of Takeda Pharmaceutical by 46.3% in the third quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after buying an additional 49,871 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

TAK opened at $13.68 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a market cap of $43.51 billion, a PE ratio of 23.58, a P/E/G ratio of 0.25 and a beta of 0.51. The business has a fifty day simple moving average of $13.30 and a 200-day simple moving average of $13.89. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%. As a group, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.55 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.